TCRX
TScan Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.31
−6.48%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.26
- Revenue estimate
- $459.0K
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.23
- EPS estimate
- -$0.25
- Revenue actual
- $1.1M
- Revenue estimate
- $1.9M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- +15.6%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Hold
- Price target
- $2.67
- PT range
- $1.00 – $6.00
- Analysts
- 3
0 Buy3 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.25 | -$0.23 | Beat 9.23% | $1.1M |
| May 6, 2026 | -$0.22 | -$0.22 | In line | $982.0K |
| Mar 4, 2026 | -$0.27 | -$0.18 | Beat 33.33% | $2.6M |
| Nov 12, 2025 | -$0.35 | -$0.28 | Beat 20.00% | $2.5M |
| Aug 12, 2025 | -$0.28 | -$0.28 | In line | $3.1M |
| Mar 5, 2025 | -$0.27 | -$0.29 | Miss -7.41% | $665.0K |
| Mar 6, 2024 | -$0.30 | -$0.21 | Beat 30.00% | $7.2M |
| Nov 9, 2023 | -$0.43 | -$0.24 | Beat 44.19% | $3.9M |
| Aug 10, 2023 | -$0.76 | -$0.51 | Beat 32.89% | $3.1M |
| Mar 8, 2023 | -$0.73 | -$0.78 | Miss -6.85% | — |
| Nov 9, 2022 | -$0.73 | -$0.67 | Beat 8.22% | $3.4M |
| Aug 10, 2022 | -$0.76 | -$0.63 | Beat 17.11% | $4.1M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026